CIK: 0001595851
Total reported value
$331.0M
Reporting period: 2024-09-30 · Number of holdings: 54
Ghost Tree Capital, LLC disclosed 54 holdings in its latest 13F filing for the period ending 2024-09-30, with total reported value of $331.0M and a quarterly turnover rate of 0.0%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "G"
Ghost Tree Capital, LLC's disclosed holdings carry a Herfindahl concentration index of 0.031 — mathematically equivalent to about 32 equally-sized positions, well below its 54 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 0.81), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 24% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
No holding changes this quarter
Showing top 52 holdings (of 54 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 8.95% | — | — | |
| 2 | ✓ | Biohaven LTD | Stock-Other | 5.26% | — | — | |
| 3 | SRPT | Sarepta Therapeutics INC | Stock-Healthcare | 4.53% | — | +118.18% | |
| 4 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 3.96% | — | — | |
| 5 | 2655787D | Blueprint Medicines CORP | Stock-Other | 3.91% | — | +250.00% | |
| 6 | AXSM | Axsome Therapeutics INC | Stock-Healthcare | 3.66% | — | -10.00% | |
| 7 | TARS | Tarsus Pharmaceuticals INC | Stock-Other | 3.48% | — | +48.94% | |
| 8 | CATX | Perspective Therapeutics INC | Stock-Other | 3.02% | — | -18.92% | |
| 9 | CGON | Cg Oncology INC | Stock-Other | 2.85% | — | -3.85% | |
| 10 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 2.79% | — | -20.00% | |
| 11 | PCVX | Vaxcyte INC | Stock-Other | 2.76% | — | -46.67% | |
| 12 | INSM | Insmed INC | Stock-Healthcare | 2.76% | — | -52.83% | |
| 13 | VKTX | Viking Therapeutics INC | Stock-Healthcare | 2.68% | — | +47.37% | |
| 14 | SNDX | Syndax Pharmaceuticals INC | Stock-Other | 2.62% | — | +28.57% | |
| 15 | JANX | Janux Therapeutics INC | Stock-Other | 2.61% | — | +280.00% | |
| 16 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 2.37% | — | +117.14% | |
| 17 | ASND | Ascendis Pharma A/S | Stock-Other | 2.37% | — | -39.46% | |
| 18 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 2.32% | — | -37.50% | |
| 19 | SLNOEUR | Soleno Therapeutics INC | Stock-Other | 2.29% | — | -50.00% | |
| 20 | TGTX | Tg Therapeutics INC | Stock-Healthcare | 2.19% | — | -38.00% | |
| 21 | RZLT | Rezolute INC | Stock-Other | 2.16% | — | +3.76% | |
| 22 | PHAT | Phathom Pharmaceuticals INC | Stock-Other | 2.05% | — | -37.50% | |
| 23 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.96% | — | -57.20% | |
| 24 | OLMA | Olema Pharmaceuticals INC | Stock-Other | 1.93% | — | -2.73% | |
| 25 | IMVT | Immunovant INC | Stock-Other | 1.85% | — | -17.31% | |
| 26 | EWTX | Edgewise Therapeutics INC | Stock-Other | 1.57% | — | — | |
| 27 | REPL | Replimune Group INC | Stock-Other | 1.49% | — | — | |
| 28 | BBIO | Bridgebio Pharma INC | Stock-Healthcare | 1.35% | — | +25.00% | |
| 29 | TSHA | Taysha Gene Therapies INC | Stock-Other | 1.31% | — | +72.00% | |
| 30 | RYTM | Rhythm Pharmaceuticals INC | Stock-Other | 1.25% | — | -32.84% | |
| 31 | ANNX | Annexon INC | Stock-Other | 1.16% | — | +23.93% | |
| 32 | KRRO | Korro Bio INC | Stock-Other | 1.11% | — | +10.00% | |
| 33 | DYN | Dyne Therapeutics INC | Stock-Other | 1.09% | — | — | |
| 34 | ARVN | Arvinas INC | Stock-Other | 1.08% | — | +93.33% | |
| 35 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.95% | — | — | |
| 36 | NUVB | Nuvation Bio INC | Stock-Other | 0.93% | — | +17.39% | |
| 37 | SVRA | Savara INC | Stock-Other | 0.93% | — | -31.01% | |
| 38 | TNYA | Tenaya Therapeutics INC | Stock-Other | 0.87% | — | +11.11% | |
| 39 | RGNX | Regenxbio INC | Stock-Other | 0.84% | — | +55.88% | |
| 40 | CRVS | Corvus Pharmaceuticals INC | Stock-Other | 0.80% | — | — | |
| 41 | ABSI | Absci CORP | Stock-Other | 0.63% | — | — | |
| 42 | NGNE | Neurogene INC | Stock-Other | 0.63% | — | -28.57% | |
| 43 | CAPR | Capricor Therapeutics INC | Stock-Other | 0.57% | — | — | |
| 44 | APLSUSD | Apellis Pharmaceuticals INC | Stock-Other | 0.57% | — | -51.85% | |
| 45 | SMMT | Summit Therapeutics INC | Stock-Other | 0.56% | — | — | |
| 46 | SYRE | Spyre Therapeutics INC | Stock-Other | 0.53% | — | -76.02% | |
| 47 | VRDN | Viridian Therapeutics INC | Stock-Other | 0.52% | — | -87.24% | |
| 48 | ✓ | Proqr Thrapeutics N V | Stock-Other | 0.49% | — | -1.37% | |
| 49 | ATYR | Atyr Pharma INC | Stock-Other | 0.43% | — | — | |
| 50 | LRMR | Larimar Therapeutics INC | Stock-Other | 0.40% | — | — |
Performance for Q3 2026
+15.1%
Performance Last 4 Quarters
+72.5%
Based on 76% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2024-09-30 | 54 | $331.0M | 0 | |
| 2024-06-30 | 63 | $319.3M | 0 | |
| 2024-03-31 | 72 | $361.3M | 0 | |
| 2023-12-31 | 52 | $305.9M | 0 | |
| 2023-09-30 | 70 | $304.1M | 0 | |
| 2023-06-30 | 57 | $302.9M | 0 | |
| 2023-03-31 | 58 | $338.3M | 0 | |
| 2022-12-31 | 35 | $234.2M | 0 | |
| 2022-09-30 | 44 | $356.3M | 0 | |
| 2022-06-30 | 34 | $192.0M | 0 | |
| 2022-03-31 | 42 | $460.8M | 0 | |
| 2021-12-31 | 47 | $279.0M | 0 | |
| 2021-09-30 | 60 | $342.0M | 0 | |
| 2021-06-30 | 52 | $363.8M | 0 | |
| 2021-03-31 | 50 | $425.5M | 100 | |
| 2020-12-31 | 43 | $448.8M | 89 | |
| 2020-09-30 | 47 | $346.0M | 78 | |
| 2020-06-30 | 43 | $379.0M | 67 | |
| 2020-03-31 | 49 | $377.0M | 83 | |
| 2019-12-31 | 52 | $525.1M | 96 | |
| 2019-09-30 | 44 | $392.5M | 82 | |
| 2019-06-30 | 43 | $482.1M | 93 | |
| 2019-03-31 | 39 | $382.8M | 97 | |
| 2018-12-31 | 40 | $275.5M | 89 | |
| 2018-09-30 | 55 | $470.5M | 79 | |
| 2018-06-30 | 46 | $339.8M | 100 | |
| 2018-03-31 | 53 | $494.3M | 100 | |
| 2017-12-31 | 49 | $426.4M | 100 | |
| 2017-09-30 | 63 | $470.9M | 99 | |
| 2017-06-30 | 66 | $481.1M | 97 | |
| 2017-03-31 | 64 | $536.5M | 99 | |
| 2016-12-31 | 70 | $415.5M | 91 | |
| 2016-09-30 | 88 | $616.6M | 99 | |
| 2016-06-30 | 63 | $346.3M | 100 | |
| 2016-03-31 | 51 | $176.7M | 100 | |
| 2015-12-31 | 47 | $244.2M | 100 | |
| 2015-09-30 | 74 | $222.2M | 100 | |
| 2015-06-30 | 69 | $308.6M | 100 | |
| 2015-03-31 | 64 | $278.1M | 100 | |
| 2014-12-31 | 59 | $208.4M | 100 | |
| 2014-09-30 | 70 | $184.2M | 100 | |
| 2014-06-30 | 54 | $141.8M | 100 | 178462F26285303G0083B |
| 2014-03-31 | 65 | $168.4M | 100 | |
| 2013-12-31 | 62 | $162.5M | 0 |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-16 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-11 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-08-11 | Amendment | View on EDGAR |
| 2021-03-31 | 2021-05-14 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-18 | Amendment | View on EDGAR |
| 2020-12-31 | 2021-02-16 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-16 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-14 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-05-15 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-04-09 | Amendment | View on EDGAR |
| 2019-12-31 | 2020-02-14 | 13F-HR | View on EDGAR |
| 2019-09-30 | 2020-04-09 | Amendment | View on EDGAR |
| 2019-09-30 | 2019-11-14 | 13F-HR | View on EDGAR |
| 2019-06-30 | 2020-04-09 | Amendment | View on EDGAR |
| 2019-06-30 | 2019-08-14 | 13F-HR | View on EDGAR |
| 2019-03-31 | 2020-04-09 | Amendment | View on EDGAR |
| 2019-03-31 | 2019-05-15 | 13F-HR | View on EDGAR |
| 2018-12-31 | 2020-04-09 | Amendment | View on EDGAR |
| 2018-12-31 | 2019-02-14 | 13F-HR | View on EDGAR |
| 2018-09-30 | 2020-04-09 | Amendment | View on EDGAR |
| 2018-09-30 | 2018-11-14 | 13F-HR | View on EDGAR |
| 2018-06-30 | 2018-08-14 | 13F-HR | View on EDGAR |
| 2018-03-31 | 2018-05-15 | 13F-HR | View on EDGAR |
| 2017-12-31 | 2018-02-14 | 13F-HR | View on EDGAR |
| 2017-09-30 | 2017-11-14 | 13F-HR | View on EDGAR |
| 2017-06-30 | 2017-08-14 | 13F-HR | View on EDGAR |
| 2017-03-31 | 2017-05-15 | 13F-HR | View on EDGAR |
| 2016-12-31 | 2017-02-14 | 13F-HR | View on EDGAR |
| 2016-09-30 | 2016-11-14 | 13F-HR | View on EDGAR |
| 2016-06-30 | 2016-08-12 | 13F-HR | View on EDGAR |
| 2016-03-31 | 2016-05-16 | Amendment | View on EDGAR |
| 2016-03-31 | 2016-05-13 | 13F-HR | View on EDGAR |
| 2015-12-31 | 2016-02-17 | Amendment | View on EDGAR |
| 2015-12-31 | 2016-02-16 | 13F-HR | View on EDGAR |
| 2015-09-30 | 2015-11-16 | 13F-HR | View on EDGAR |
| 2015-06-30 | 2015-09-09 | Amendment | View on EDGAR |
| 2015-06-30 | 2015-08-14 | 13F-HR | View on EDGAR |
| 2015-03-31 | 2015-05-15 | 13F-HR | View on EDGAR |
| 2015-03-31 | 2015-05-15 | Amendment | View on EDGAR |
| 2014-12-31 | 2015-02-18 | Amendment | View on EDGAR |
| 2014-12-31 | 2015-02-17 | 13F-HR | View on EDGAR |
| 2014-09-30 | 2014-11-14 | 13F-HR | View on EDGAR |
| 2014-06-30 | 2014-08-14 | 13F-HR | View on EDGAR |
| 2014-03-31 | 2014-05-15 | 13F-HR | View on EDGAR |
| 2013-12-31 | 2014-05-01 | Amendment | View on EDGAR |
| 2013-12-31 | 2014-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001792851
Total reported value
$331.1M
76 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001705929
Total reported value
$330.9M
91 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001750312
Total reported value
$330.9M
28 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0000096223
Total reported value
$14.6B
1,692 stks
2026-03-31
1 of the top 5 holdings overlap, including Ss Spdr S&p Biotech ETF
CIK 0000860645
Total reported value
$83.5M
21 stks
2026-03-31
1 of the top 5 holdings overlap, including Ss Spdr S&p Biotech ETF
CIK 0001135986
Total reported value
$522.2M
503 stks
2014-09-30
Stale — no recent filing
1 of the top 5 holdings overlap, including Novo-nordisk A/s-spons Adr